ENACE ENACE ENPRIL ENPRIL ZEPRES PLUS ZEPRES ZEPRES ZEPRES CARDIL CARDIL MEDIPRIL STADELANT STADELANT CO AMOTAC AMOTAC RENITEC RENITEC RENITEC CO-RENITEC CORTEC CORTEC CORTEC PLUS REDOPRIL ACELAR ACELAR HIPRIL HIPRIL ALPHRIN CARDACE-H CARDACE CARDACE CO-CARDIOTEC CARDIOTEC CARDIOTEC CO-ZEAL LOPRITOL NAPRIL NAPRIL VASOPRIL VASOPRIL LAPORIDE JAPRIL JAPRIL CONIUREN CONIUREN MAXPRIL MAXPRIL ENETEC ENETEC SHOZUPRIL

Dose: 2.5 mg
Single Dose: 2.5 (2.5)
Frequency: 24 hourly
Route: PO
Instructions: Initial

Dose: 80 to 50 mcg/kg
Single Dose: 65 (65)
Frequency: 24 hourly
Route:
Instructions:

. It is of Synthetic origin and belongs to Phenylpropyl Amino acid. It belongs to Angiotensin converting enzyme inhibitor-ACEI pharmacological group on the basis of mechanism of action and also classified in Antihypertensive Agents pharmacological group.The Molecular Weight of Enalapril (Maleate) is 492.50. Its pKa is 3.0, 5.4.

Enalapril (Maleate) is contraindicated in conditions like Angioneurotic edema,Aortic stenosis,Bilateral renal artey stenosis.

The severe or irreversible adverse effects of Enalapril (Maleate), which give rise to further complications include Hepatotoxicity, Anaphylactoid reactions, Vasculitis, Angioedema, Neutropenia, Acute renal failure, Hepatotoxicity, Angioedema.The signs and symptoms that are produced after the acute overdosage of Enalapril (Maleate) include Hypotension.The symptomatic adverse reactions produced by Enalapril (Maleate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Rashes, Dry cough, Taste disturbances, Azotemia, dizziness.

Enalapril (Maleate) is primarily indicated in conditions like Congestive heart failure, Diabetic retinopathy, Essential hypertension, Heart failure (adjunct), Hypertension, Left ventricular dysfunction, NSAID-associated gastric and duodenal ulcers, Renal hypertension, Severe or recurrent duodenal and gastric ulcertion, and can also be given in adjunctive therapy as an alternative drug of choice in Essential and renovascular hypertension.

Enalapril (Maleate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAllopurinolAlprostadilEnhanced hypotensive effects when alprostadil given with ACE inhibitors (e.g Enalapril)Amiloride (HCl)enalapril can reduce potassium loss with thiazide diuretics (e.g amiloride, spiranolactone, triametrene) may result in hyperkalemiaAspirinRisk of renal impairment when Aspirin (in doses over 300mg daily) given with ACE inhibitors (e.g Fosinopril), also hypotensive effects antagonized by aspirin and other NSaids by blocking prostraglandins production. the combination of aspirin with enalapril may result in nephrotoxityCyclosporin ADiazoxideEnhanced hypotensive effect when Diazoxide given with Enalapril.Digoxinenalapril reduce clearance of digoxin leading to increase serum level of digoxin in patients with heart failureEplerenoneEplerenone may enhance hyperkalaemic effect of ACE inhibitors, angiotensin II receptor blockers, potassium-sparing diuretics or potassium salts.Monitor serum potassium levels and adjust doses.IndomethacinIron DextranIron SorbitolLithiumcoadministration may increase lithium plasma level and lithium toxcity occurlithium levels should be monitoredPotassium GlycerophosphateConcurrent use may cause too much potassium in the blood.RifampicinTechnetium Succimer Tc-99mIn patients with unilateral renal artery stenosis, use of Enalapril (Maleate) may result in decreased uptake of technetium Tc 99m succimer by the affected kidney because of a loss of effective trans-membrane filtration pressure. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Increased Serum Potassium Level

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab, Inj Store at room temperature, Below 30°C.

Enalapril should be used with caution in patients of renal insufficiency, severe liver dysfunction, hypervolemia, angioedema and in pre-existing bone marrow depression. Enalapril therapy can cause neutropenia or agranulocytosis. Patients with renal disease, patients with immunosuppression or receiving immunosuppressives, and patients with collagen vascular disease or autoimmune disease are at a greater risk for developing these complications. The dose should be adjusted in patients with renal impairment. It should be used cautiously in patients with congestive heart failure. Initial doses should be lower than in the treatment of hypertension becauseof a greater risk of developing hypotension. It should not be administered to patients with pre-existing renal artery stenosis. Renal function should be monitored closely during the first 2 weeks after initiating therapy. It should be discontinued if renal function worsens acutely. Other types of renal disease can actually improve during Enalapril therapy. The dose should be adjusted in patients with renal impairment. It should be used with caution patients with hyperkalemia. It is classified as pregnancy category C and should be used with caution during pregnancy only if clearly needed.